Bayer reports more positive PhIII data for hypertension contender; Shire commits $22M to rare disease alliance in Italy;

Conversations on Twitter :

 @FierceBiotech: Industry Voices: Biosimilars and Trade Secrets. Feature | Follow @FierceBiotech

 @JohnCFierce: ZS Pharma down in Fort Worth raised $46M in venture funds for clinical trial of kidney, liver disease drug. | Follow @JohnCFierce

 @RyanMFierce: Radius has set its biotech IPO range $8.50-$10.50. Will it hit its price target and keep the streak alive? More | Follow @RyanMFierce

> After reporting upbeat Phase III results in PAH, Bayer has reported success in a late-stage study for patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or those with persistent or recurrent pulmonary hypertension (PH) after surgery with the same experimental drug, riociguat. Release

> Eyeing the growing healthcare market in China, MicuRx Pharmaceuticals, a developer of antibiotics and Shanghai MengKe Pharmaceuticals have formed a joint venture to commercialize a candidate dubbed MRX-I in the Asian country. Item

> Bristol-Myers Squibb ($BMY) fell to a third-quarter loss in part because of its failed Hepatitis C program involving assets acquired in its $2.5 billion buyout of Inhibitex.  Article

> Shire ($SHPG) has pledged $22 million over 5 years to support an alliance with a Italian biomedical charity, the Fondazion Telethon, to research new therapies for rare diseases. Release

> Pearl Therapeutics (a 2011 Fierce 15 company) has wrapped up a final Phase IIb study of its lead COPD therapy called PT003 and selected a dose for late-stage development of the experimental treatment. Release

> Cambridge, MA-based biotech Radius Health, which is developing an osteoporosis therapy, has set a price range of $8.50 to $10.50 for its initial public offering. Report

Pharma News

@FiercePharma: More pain for Big Pharma sales: Lilly's drop 11%, earnings fall short. Not as bad as BMS, though. More | Follow @FiercePharma

> Pharma wheels and deals in Europe as austerity wears on. Story

> GOP or Dem? Some pharma donors don't hedge their bets. Article

> BMS results crater on 96% drop in Plavix sales. News

Medical Device News

 @FierceMedDev: The FDA says it will focus more on quality in the device approval process. What that means may be an open question. More | Follow @FierceMedDev

 @MarkHFierce: A medical device regulatory scandal erupts in Great Britain. Report | Follow @MarkHFierce

 @DamianFierce: Thermo Fisher beats the Street again on soaring diagnostics sales. More | Follow @DamianFierce

> St. Jude's heart-plug future hinges on study data. Story

> EU notified bodies accused of improperly competing for device business. Article

> Bard nabs Neomend for $140M. News

> Zoll Medical launches Japan division. Report

Drug Delivery News

> Fuse Science rolls out roll-on delivery. News

> Biotecnol and PolyTherics team up to develop drug conjugates. Story

> Antibiotic Trojan horse for cholera may be possible. Item

> Oral flu vaccine melts in your mouth. More

Biomarkers News

> Genes might not be the key to antidepressant success after all. Story

> Blood test could predict breast cancer 20 years early. More

> Blood antibody pinpoints deadly preeclampsia. Article

> Researchers seek new pancreatic cancer biomarkers. Item

And Finally… A new Harvard study highlights to role of genetics in the placebo effect, which has befuddled drug developers for decades. Item

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.